Advantages and applications of CAR-expressing natural killer cells

Frontiers in Pharmacology

Volumn 6, Issue FEB, 2015, Pages

  Glienke, Wolfgang ^a   Esser, Ruth ^a   Priesner, Christoph ^a   Suerth, Julia D ^a   Schambach, Axel ^a   Wels, Winfried S ^b   Grez, Manuel ^b   Kloess, Stephan ^a   Arseniev, Lubomir ^a   Koehl, Ulrike ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

CAR; NK cells; Suicide genes; T cells

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ARTICLE; CELL ENGINEERING; CELL THERAPY; CYTOTOXICITY; GENE INSERTION; GENE SWITCHING; HUMAN; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SUICIDE GENE; T CELL DEPLETION; T LYMPHOCYTE;

EID: 84926457446     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00021     Document Type: Article

References (81)

1. Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C.,et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151. doi: 10.1126/science.1233151
2. Alsamah, W., and Romia, Y. (2014). Modification of natural killer cells to target tumors. Int. J. Pharm. Clin. Res. 6, 97-100.
3. Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S.,et al. (2009). 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin. Cancer Res. 15, 4857-4866. doi: 10.1158/1078-0432.CCR-08-2810
4. Battula, V. L., Shi, Y., Evans, K. W., Wang, R. Y., Spaeth, E. L., Jacamo, R. O.,et al. (2012). Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J. Clin. Invest. 122, 2066-2078. doi: 10.1172/JCI59735
5. Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T.,et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158. doi: 10.1126/science.1233158
6. Boissel, L., Betancur-Boissel, M., Lu, W., Krause, D. S., Van Etten, R. A., Wels, W. S.,et al. (2013). Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2, e26527. doi: 10.4161/onci.26527
7. Boissel, L., Betancur, M., Wels, W. S., Tuncer, H., and Klingemann, H. (2009). Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk. Res. 33, 1255-1259. doi: 10.1016/j.leukres.2008.11.024
8. Bonini, C., Bondanza, A., Perna, S. K., Kaneko, S., Traversari, C., Ciceri, F.,et al. (2007). The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol. Ther. 15, 1248-1252. doi: 10.1038/sj.mt.6300190
9. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L.,et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724. doi: 10.1126/science.276.5319.1719
10. Braun, C. J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M.,et al. (2014). Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity. Sci Trans. Med. 6, 227ra233. doi: 10.1126/scitranslmed.3007280
11. Brehm, C., Huenecke, S., Esser, R., Kloess, S., Quaiser, A., Betz, S.,et al. (2014). Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. Cancer Immunol. Immunother. 63, 821-833. doi: 10.1007/s00262-014-1556-5
12. Brehm, C., Huenecke, S., Quaiser, A., Esser, R., Bremm, M., Kloess, S.,et al. (2011). IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS ONE 6:e27351. doi: 10.1371/journal.pone.0027351
13. Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., and Sadelain, M. (2010). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666-668. doi: 10.1038/mt.2010.31
14. Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F.,et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318-322. doi: 10.1038/nature09328
15. Cheng, M., Zhang, J., Jiang, W., Chen, Y., and Tian, Z. (2012). Natural killer cell lines in tumor immunotherapy. Front. Med. 6:56. doi: 10.1007/s11684-012-0177-7
16. Chang, Y. H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., and Campana, D. (2013). A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 73, 1777-1786. doi: 10.1158/0008-5472.CAN-12-3558
17. Chouaib, S., Pittari, G., Nanbakhsh, A., El Ayoubi, H., Amsellem, S., Bourhis, J. H.,et al. (2014). Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front. Immunol. 5:95. doi: 10.3389/fimmu.2014.00095
18. Chu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J.,et al. (2014a). CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28, 917-927. doi: 10.1038/leu.2013.279
19. Chu, Y., Yahr, A., Ayello, J., van de Ven, C., Barth, M., Czuczman M.,et al. (2014b). Anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells significantly mediate rituximab sensitive and resistant burkitt lymphoma (BL) regression and improve survival in human BL xenografted NSG mice. Cytotherapy 16:4. doi: 10.1016/j.jcyt.2014.01.064
20. Corrigan-Curay, J., Kiem, H. P., Baltimore, D., O'reilly, M., Brentjens, R. J., Cooper, L.,et al. (2014). T-cell immunotherapy: looking forward. Mol. Ther. 22, 1564-1574. doi: 10.1038/mt.2014.148
21. Di Stasi, A., Tey, S. K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C.,et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683. doi: 10.1056/NEJMoa1106152
22. Esser, R., Muller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D.,et al. (2012). NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J. Cell Mol. Med. 16, 569-581. doi: 10.1111/j.1582-4934.2011.01343.x
23. Fan, L., Freeman, K. W., Khan, T., Pham, E., and Spencer, D. M. (1999). Improved artificial death switches based on caspases and FADD. Hum. Gene Ther. 10, 2273-2285. doi: 10.1089/10430349950016924
24. Ferrara, J. L., Levine, J. E., Reddy, P., and Holler, E. (2009). Graft-versus-host disease. Lancet 373, 1550-1561. doi: 10.1016/S0140-6736(09)60237-3
25. Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R.,et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518. doi: 10.1056/NEJMoa1215134
26. Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E.,et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142. doi: 10.1172/JCI35700
27. Hacein-Bey-Abina, S., Pai, S. Y., Gaspar, H. B., Armant, M., Berry, C. C., Blanche, S.,et al. (2014). A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N. Engl. J. Med. 371, 1407-1417. doi: 10.1056/NEJMoa1404588
28. Holdenrieder, S., Eichhorn, P., Beuers, U., Samtleben, W., Stieber, P., Nagel, D.,et al. (2007). Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer. Res. 27, 2041-2045.
29. Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H.,et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150. doi: 10.1172/JCI35798
30. Huenecke, S., Zimmermann, S. Y., Kloess, S., Esser, R., Brinkmann, A., Tramsen, L.,et al. (2010). IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16-subpopulations and in vivo influence after haploidentical NK cell infusion. J. Immunother. 33, 200-210. doi: 10.1097/CJI.0b013e3181bb46f7
31. Imai, C., Iwamoto, S., and Campana, D. (2005). Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376-383. doi: 10.1182/blood-2004-12-4797
32. Irving, B. A., Chan, A. C., and Weiss, A. (1993). Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J. Exp. Med. 177, 1093-1103. doi: 10.1084/jem.177.4.1093
33. Iyengar, R., Handgretinger, R., Babarin-Dorner, A., Leimig, T., Otto, M., Geiger, T. L.,et al. (2003). Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 5, 479-484. doi: 10.1080/14653240310003558
34. Jiang, H., Zhang, W., Shang, P., Zhang, H., Fu, W., Ye, F.,et al. (2014). Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol. Oncol. 8, 297-310. doi: 10.1016/j.molonc.2013.12.001
35. Jones, B. S., Lamb, L. S., Goldman, F., and Di Stasi, A. (2014). Improving the safety of cell therapy products by suicide gene transfer. Front. Pharmacol. 5:254. doi: 10.3389/fphar.2014.00254
36. Kenderian, S. S., Ruella, M., Gill, S., and Kalos, M. (2014). Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res. 74, 6383-6389. doi: 10.1158/0008-5472.CAN-14-1530
37. Klingemann, H. (2014). Are natural killer cells superior CAR drivers? Oncoimmunology 3, e28147. doi: 10.4161/onci.28147
38. Kloess, S., Huenecke, S., Piechulek, D., Esser, R., Koch, J., Brehm, C.,et al. (2010). IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur. J. Immunol. 40, 3255-3267. doi: 10.1002/eji.201040568
39. Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G.,et al. (2013). Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129-4139. doi: 10.1182/blood-2013-08-519413
40. Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I.,et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720. doi: 10.1182/blood-2011-10-384388
41. Koehl, U., Brehm, C., Huenecke, S., Zimmermann, S. Y., Kloess, S., Bremm, M.,et al. (2013). Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front. Oncol. 3:118. doi: 10.3389/fonc.2013.00118
42. Koehl, U., Esser, R., Zimmermann, S., Tonn, T., Kotchetkov, R., Bartling, T.,et al. (2005). Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin. Padiatr. 217, 345-350. doi: 10.1055/s-2005-872520
43. Koehl, U., Sorensen, J., Esser, R., Zimmermann, S., Gruttner, H. P., Tonn, T.,et al. (2004). IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol. Dis. 33, 261-266. doi: 10.1016/j.bcmd.2004.08.013
44. Kornbluth, J., Spear, B., Raab, S. S., and Wilson, D. B. (1985). Evidence for the role of class I and class II HLA antigens in the lytic function of a cloned line of human natural killer cells. J. Immunol. 134, 728-735.
45. Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B.,et al. (2008). Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl. Acad. Sci. U.S.A. 105, 17481-17486. doi: 10.1073/pnas.0804788105
46. Leuci, V., Mesiano, G., Gammaitoni, L., Aglietta, M., and Sangiolo, D. (2014). Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. Curr. Gene Ther. 14, 52-62. doi: 10.2174/1566523213666131223130353
47. Leung, S. O., Gao, K., Wang, G. Y., Cheung, B. K., Lee, K. Y., Zhao, Q.,et al. (2014). Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody. MAbs 7, 66-76. doi: 10.4161/19420862.2014.985519
48. Leung, W. (2011). Use of NK cell activity in cure by transplant. Br. J. Haematol. 155, 14-29. doi: 10.1111/j.1365-2141.2011.08823.x
49. Li, L., Liu, L. N., Feller, S., Allen, C., Shivakumar, R., Fratantoni, J.,et al. (2010). Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 17, 147-154. doi: 10.1038/cgt.2009.61
50. Lipowska-Bhalla, G., Gilham, D. E., Hawkins, R. E., and Rothwell, D. G. (2012). Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol. Immunother. 61, 953-962. doi: 10.1007/s00262-012-1254-0
51. Luetke-Eversloh, M., Killig, M., and Romagnani, C. (2013). Signatures of human NK cell development and terminal differentiation. Front. Immunol. 4:499. doi: 10.3389/fimmu.2013.00499
52. Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J.,et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517. doi: 10.1056/NEJMoa1407222
53. Maus, M. V., Grupp, S. A., Porter, D. L., and June, C. H. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625-2635. doi: 10.1182/blood-2013-11-492231
54. Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., Mcnearney, S. A., Yun, G. H., Fautsch, S. K.,et al. (2005). Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057. doi: 10.1182/blood-2004-07-2974
55. Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C., and Rosenberg, S. A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851. doi: 10.1038/mt.2010.24
56. Muller, T., Uherek, C., Maki, G., Chow, K. U., Schimpf, A., Klingemann, H. G.,et al. (2008). Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol. Immunother. 57, 411-423. doi: 10.1007/s00262-007-0383-3
57. Ni, Z., Knorr, D. A., Bendzick, L., Allred, J., and Kaufman, D. S. (2014). Expression of chimeric receptor CD4zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells 32, 1021-1031. doi: 10.1002/stem.1611
58. Park, T. S., Rosenberg, S. A., and Morgan, R. A. (2011). Treating cancer with genetically engineered T cells. Trends Biotechnol. 29, 550-557. doi: 10.1016/j.tibtech.2011.04.009
59. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., and June, C. H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733. doi: 10.1056/NEJMoa1103849
60. Raffaghello, L., Prigione, I., Airoldi, I., Camoriano, M., Levreri, I., Gambini, C.,et al. (2004). Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6, 558-568. doi: 10.1593/neo.04316
61. Sadelain, M., Brentjens, R., and Riviere, I. (2013). The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388-398. doi: 10.1158/2159-8290.CD-12-0548
62. Sahm, C., Schonfeld, K., and Wels, W. S. (2012). Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol. Immunother. 61, 1451-1461. doi: 10.1007/s00262-012-1212-x
63. Schonfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M.,et al. (2014). Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol. Ther. doi: 10.1038/mt.2014.219 [Epub ahead of print].
64. Schule, S., Renner, M., Longhurst, S., and Narayanan, G. (2010). Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53, 30-37. doi: 10.1007/s00103-009-0988-0
65. Shah, N. N., Baird, K., Delbrook, C. P., Fleisher, T. A., Kohler, M. E., Rampertaap, S.,et al. (2014). Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T cell depleted stem cell transplantation. Blood doi: 10.1182/blood-2014-07-592881 [Epub ahead of print].
66. Shimasaki, N., and Campana, D. (2013). Natural killer cell reprogramming with chimeric immune receptors. Methods Mol. Biol. 969, 203-220. doi: 10.1007/978-1-62703-260-5_13
67. Shimasaki, N., Fujisaki, H., Cho, D., Masselli, M., Lockey, T., Eldridge, P.,et al. (2012). A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 14, 830-840. doi: 10.3109/14653249.2012.671519
68. Spanholtz, J., Preijers, F., Tordoir, M., Trilsbeek, C., Paardekooper, J., De Witte, T.,et al. (2011). Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS ONE 6:e20740. doi: 10.1371/journal.pone.0020740
69. Stauss, H. J., and Morris, E. C. (2013). Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther. 20, 1029-1032. doi: 10.1038/gt.2013.34
70. Stein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A.,et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198-204. doi: 10.1038/nm.2088
71. Stern, M., Passweg, J. R., Meyer-Monard, S., Esser, R., Tonn, T., Soerensen, J.,et al. (2013). Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant. 48, 433-438. doi: 10.1038/bmt.2012.162
72. Suerth, J. D., Schambach, A., and Baum, C. (2012). Genetic modification of lymphocytes by retrovirus-based vectors. Curr. Opin. Immunol. 24, 598-608. doi: 10.1016/j.coi.2012.08.007
73. Sutlu, T., Stellan, B., Gilljam, M., Quezada, H. C., Nahi, H., Gahrton, G.,et al. (2010). Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 12, 1044-1055. doi: 10.3109/14653249.2010.504770
74. Tassev, D. V., Cheng, M., and Cheung, N. K. (2012). Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther. 19, 84-100. doi: 10.1038/cgt.2011.66
75. Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U.,et al. (2013). Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15, 1563-1570. doi: 10.1016/j.jcyt.2013.06.017
76. Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H. G.,et al. (2002). Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100, 1265-1273.
77. Velardi, A. (2012). Natural killer cell alloreactivity 10 years later. Curr. Opin. Hematol. 19, 421-426. doi: 10.1097/MOH.0b013e3283590395
78. Vogler, I., Newrzela, S., Hartmann, S., Schneider, N., Von Laer, D., Koehl, U.,et al. (2010). An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol. Ther. 18, 1330-1338. doi: 10.1038/mt.2010.83
79. Woll, P. S., Grzywacz, B., Tian, X., Marcus, R. K., Knorr, D. A., Verneris, M. R.,et al. (2009). Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 113, 6094-6101. doi: 10.1182/blood-2008-06-165225
80. Yagita, M., Huang, C. L., Umehara, H., Matsuo, Y., Tabata, R., Miyake, M.,et al. (2000). A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14, 922-930. doi: 10.1038/sj.leu.2401769
81. Zhang, G., Liu, R., Zhu, X., Wang, L., Ma, J., Han, H.,et al. (2013). Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol. Cell Biol. 91, 615-624. doi: 10.1038/icb.2013.45